NEW YORK (GenomeWeb) – In an investor note released this week, investment bank Piper Jaffray projected solid growth in 2015 for Fluidigm's CyTOF mass spectrometry platform.

The projection is based primarily on what Piper Jaffray sees as growing academic acceptance of the platform, based on a significant increase in publications using the instrument. The firm noted as well that it believes placing additional instruments with existing customers represents a significant opportunity for Fluidigm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.